/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Research To Practice | Oncology Videos
  2. Non-Small Cell Lung Cancer — A Presentation by Dr Julia Rotow on the Potential Role of PD-1 x VEGF Bispecific Antibodies
Non-Small Cell Lung Cancer — A Presentation by Dr Julia Rotow on the Potential Role of PD-1 x VEGF Bispecific Antibodies

Non-Small Cell Lung Cancer — A Presentation by Dr Julia Rotow on the Potential Role of PD-1 x VEGF Bispecific Antibodies

Research To Practice | Oncology Videos · Oct 17, 2026

Novel PD-1/VEGF bispecifics like ivonescimab show survival gains over standard IO in NSCLC, reshaping front- and post-TKI treatment.

Ivonescimab Overcomes Historical VEGF Limitations by Delivering Clear Overall Survival in Squamous NSCLC

Historic VEGF inhibitors in lung cancer improved progression-free survival without yielding overall survival gains. The phase 3 HARMONY-6 trial broke this pattern by showing a statistically and clinically significant median overall survival improvement of 27 versus 23 months (hazard ratio 0.66) when combining ivonescimab with chemotherapy.

Non-Small Cell Lung Cancer — A Presentation by Dr Julia Rotow on the Potential Role of PD-1 x VEGF Bispecific Antibodies thumbnail

Non-Small Cell Lung Cancer — A Presentation by Dr Julia Rotow on the Potential Role of PD-1 x VEGF Bispecific Antibodies

Research To Practice | Oncology Videos·a month ago

Careful Patient Selection Enables Safe VEGF Inhibition in Squamous Cell Lung Cancer

Frontline VEGF inhibition was historically avoided in squamous non-small cell lung cancer due to severe bleeding risks. In the HARMONY-6 study, excluding patients with large cavitary lesions or significant hemoptysis kept severe grade 3 or higher hemorrhage and arterial thromboembolism uncommon.

Non-Small Cell Lung Cancer — A Presentation by Dr Julia Rotow on the Potential Role of PD-1 x VEGF Bispecific Antibodies thumbnail

Non-Small Cell Lung Cancer — A Presentation by Dr Julia Rotow on the Potential Role of PD-1 x VEGF Bispecific Antibodies

Research To Practice | Oncology Videos·a month ago

Ivonescimab Bispecific Immunotherapy Demonstrates Enhanced Efficacy in EGFR-Mutant CNS Metastases

Patients with EGFR-mutated lung cancer progressing on frontline TKIs frequently exhibit CNS metastases and historically respond poorly to checkpoint inhibitors. In the HARMONY trial, adding ivonescimab to chemotherapy preserved progression-free survival benefits and actually produced greater additive benefit in patients presenting with brain metastases.

Non-Small Cell Lung Cancer — A Presentation by Dr Julia Rotow on the Potential Role of PD-1 x VEGF Bispecific Antibodies thumbnail

Non-Small Cell Lung Cancer — A Presentation by Dr Julia Rotow on the Potential Role of PD-1 x VEGF Bispecific Antibodies

Research To Practice | Oncology Videos·a month ago

Frontline Chemotherapy Combinations Complicate Sequencing of Novel Bispecifics in EGFR-Mutant Disease

Although ivonescimab plus chemotherapy demonstrates efficacy following EGFR-TKI failure, oncologists display little consensus regarding its treatment line placement. Increased frontline chemotherapy usage from regimens like FLAURA2 creates sequencing dilemmas regarding whether bispecifics belong in the second line or should be reserved for later lines.

Non-Small Cell Lung Cancer — A Presentation by Dr Julia Rotow on the Potential Role of PD-1 x VEGF Bispecific Antibodies thumbnail

Non-Small Cell Lung Cancer — A Presentation by Dr Julia Rotow on the Potential Role of PD-1 x VEGF Bispecific Antibodies

Research To Practice | Oncology Videos·a month ago

Bispecific VEGF Targeting Avoids Compounding Toxicity Compared to Traditional Monoclonal Antibodies

Simultaneous targeting of VEGF and checkpoint inhibition raised concerns regarding compounded toxicities, but clinicians view the side-effect profile as familiar. Polling and trial results suggest ivonescimab's VEGF-related toxicities remain mostly low grade and are comparable to or more manageable than historical monoclonal antibodies like bevacizumab.

Non-Small Cell Lung Cancer — A Presentation by Dr Julia Rotow on the Potential Role of PD-1 x VEGF Bispecific Antibodies thumbnail

Non-Small Cell Lung Cancer — A Presentation by Dr Julia Rotow on the Potential Role of PD-1 x VEGF Bispecific Antibodies

Research To Practice | Oncology Videos·a month ago